Skip to main content
. 2017 Aug 28;77(14):1408–1415. doi: 10.1002/pros.23402

Figure 4.

Figure 4

Vascular endothelial growth factor (VEGF)‐C and VEGF‐D expression in low‐risk prostate cancer patients receiving neoadjuvant hormonal therapy (NHT) and those not receiving NHT (non‐NHT). Data are shown as mean (upper row) and SD (lower row)